Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

In Which Cancers Does Immunotherapy Hold Promise?

In Which Cancers Does Immunotherapy Hold Promise?

We previously wrote that immune checkpoint inhibitors, called immunotherapy, work in melanoma and lung cancer and added that they were showing effectiveness in many other cancers. Here we share findings on other cancer types.

- Related topic: Immunotherapy and the Cancer Vaccine

Bladder cancer

Little progress has occurred in advanced bladder cancer over the last 30 years. Most patients are older (average diagnosis age 73), and many have kidney failure. Chemotherapy is unsuitable for many because of difficult side effects. Options are few for those unable to tolerate it or worsening after initial chemotherapy.

Research in advanced urothelial bladder cancer has brought hope. The PD-L1 checkpoint inhibitor Atezolizumab rapidly shrank tumors in many patients within weeks. It was particularly effective with high tumor and immune-cell PD-L1 levels, shrinking tumors in approximately half. Average response duration is much longer than conventional chemotherapy.

The commonest side effects are appetite loss and weakness. More serious asthenia and hematological abnormalities (thrombocytopenia and low blood phosphorus) occurred in 4%. Based on these findings, the FDA in 2014 designated atezolizumab a breakthrough treatment for PD-L1-positive advanced bladder cancer. An ongoing phase III trial compares it with standard chemotherapy.

Kidney cancer

Advanced kidney cancer is malignant disease needing better treatment. The most common adult type is renal cell carcinoma. Almost 1/3 already have advanced (metastatic) disease at diagnosis, which is difficult to treat.

Some 10 years ago, the major advance was targeted therapy for metastatic renal cell carcinoma. Treatments targeting vascular endothelial growth factor (VEGF) and rapamycin (mTOR) inhibitors extended average survival from 1 year to nearly 3.

New drugs are needed to extend survival further for patients worsening despite VEGF- and mTOR-targeted treatment. Recent research suggests PD-1-directed immunotherapy may improve prospects for at least some.

A phase II study showed Nivolumab shrank tumors in approximately 20% of advanced clear cell renal cell carcinoma patients previously treated with VEGF inhibitors. The striking finding was response duration, exceeding 22 months in some. Average overall survival reached 25 months, roughly 1 year beyond responses to targeted therapy in an earlier study. The commonest treatment side effect was weakness.

Ongoing studies also investigate PD-1-directed treatment. In a phase III study of advanced renal cell carcinoma previously treated with VEGF inhibitors, Nivolumab performed better than the mTOR inhibitor Everolimus. Average survival was 25 months versus 19.6 months with Everolimus. Compared with Everolimus, however, Nivolumab may cause several treatment-related side effects.

Tumors shrank in 25% with Nivolumab versus only 5% with Everolimus. Interestingly, Everolimus delayed tumor development for the same time as Nivolumab (approximately 4 months).

Another ongoing phase III study investigates Nivolumab and Ipilimumab as initial advanced kidney cancer treatment. The FDA approved Nivolumab for advanced renal cell carcinoma in November 2015.

Liver cancer

Liver cancer is among the leading causes of cancer death worldwide, killing approximately 75.000 annually. The commonest type is hepatocellular carcinoma. The FDA has approved only Sorafenib for advanced disease, extending survival by just 3 months.

Initial findings last year suggested a promising role for Nivolumab in advanced (metastatic) hepatocellular carcinoma. One study showed tumor shrinkage in approximately 20%, with complete disappearance in two. Responses were long-lasting, almost all lasting 9 months or longer. At 1 year, 62% remained alive. Compared with historical Sorafenib response rates of only 2-3% and one-year survival of 30%, this is positive. Side effects included elevated ALT, AST and lipase.

Earlier findings suggest immunotherapy may work in some advanced liver cancers. Further studies with 400 patients will finish in 2018.

Head and neck cancer

The outlook for advanced or recurrent head and neck cancer is poor. Existing chemotherapy and cetuximab targeted treatment give average survival of 10-12 months. Few respond, and side effects are substantial.

Earlier findings indicate PD-1 checkpoint inhibitors work in head and neck cancers. One study showed Pembrolizumab, a PD-1 checkpoint inhibitor, shrank tumors in approximately 25%. Earlier Cetuximab response rates were below 13%. Only 10% had Pembrolizumab side effects such as facial swelling and pneumonitis.

These agents may work in HPV-associated head and neck cancers. An HPV-positive subgroup is known to respond better to standard treatment than HPV-negative tumors. In this study, however, Pembrolizumab worked in both HPV-positive and HPV-negative disease.

Although promising, larger studies are needed to determine whether Pembrolizmab extends survival. Two phase III trials currently compare it with standard treatments in advanced (metastatic) or recurrent head and neck cancer.

Blood cancer: Hodgkin lymphoma

Hodgkin lymphoma arises in the lymphatic system and is frequent in two age groups: 15-40 (particularly young adults in their 20s) and over 55. After diagnosis, of 5 patients, 4 survive 5 years with available treatments. Recurrence is rare after complete response, but recurrent disease is harder to treat; additional chemotherapy, radiotherapy or stem cell transplantation is then recommended.

Research suggests particularly PD-1-blocking immunotherapy may treat recurrent Hodgkin lymphoma. Hodgking lymphoma arising from certain genetic abnormalities is predicted especially vulnerable to PD-1 blockade. Data from adults with recurrent disease support this. Almost all had received 3 or more treatments, including transplantation and targeted therapy. A striking majority, of 23 patients, 20 responded to Nivolumab, and cancer disappeared entirely in 17%. At 6 months, progression occurred in only 14%.

The commonest side effects are itching and low platelet counts; serious effects are rare.

Sources

1. Powles T, Eder JP, Fine GD, et al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558-562, 2014

2. Motzer RJ, Escudier B, McDermott DF, et al; CheckMate 025 Investigators: Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803-1813, 2015

3. El-Khoueiry AB, Melero I, Crocenzi TS, et al: Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol 33, 2015 (suppl; abstr LBA101)

4. Seiwert TY, Haddad RI, Gupta S, et al: Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. J Clin Oncol 33, 2015 (suppl; abstr LBA6008)

5. Ansell SM, Lesokhin AM, Borrello I, et al: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372:311-319, 2015

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

In Which Cancers Does Immunotherapy Hold Promise?

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy